vs
Amphastar Pharmaceuticals, Inc.（AMPH）とスミス・アンド・ウェッソン（SWBI）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amphastar Pharmaceuticals, Inc.の直近四半期売上が大きい（$183.1M vs $124.7M、スミス・アンド・ウェッソンの約1.5倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 1.5%、差は11.8%）。Amphastar Pharmaceuticals, Inc.の前年同期比売上増加率が高い（-1.8% vs -3.9%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $16.3M）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs -4.8%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
スミス・アンド・ウェッソン・ブランズはアメリカ合衆国テネシー州メリービルに本社を置く米国の銃器メーカーです。米国で長い歴史を持つ有名な銃器生産企業で、民生用および法執行機関向け銃器分野で高い知名度を誇っています。
AMPH vs SWBI — 直接比較
損益計算書 — Q4 FY2025 vs Q2 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $124.7M |
| 純利益 | $24.4M | $1.9M |
| 粗利率 | 46.8% | 24.3% |
| 営業利益率 | 19.4% | 3.3% |
| 純利益率 | 13.3% | 1.5% |
| 売上前年比 | -1.8% | -3.9% |
| 純利益前年比 | -35.7% | -53.6% |
| EPS（希薄化後） | $0.51 | $0.04 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $124.7M | ||
| Q3 25 | $191.8M | $85.1M | ||
| Q2 25 | $174.4M | $140.8M | ||
| Q1 25 | $170.5M | $115.9M | ||
| Q4 24 | $186.5M | $129.7M | ||
| Q3 24 | $191.2M | $88.3M | ||
| Q2 24 | $182.4M | $159.1M | ||
| Q1 24 | $171.8M | $137.5M |
| Q4 25 | $24.4M | $1.9M | ||
| Q3 25 | $17.4M | $-3.4M | ||
| Q2 25 | $31.0M | $8.6M | ||
| Q1 25 | $25.3M | $2.1M | ||
| Q4 24 | $38.0M | $4.5M | ||
| Q3 24 | $40.4M | $-1.9M | ||
| Q2 24 | $37.9M | $27.9M | ||
| Q1 24 | $43.2M | $7.9M |
| Q4 25 | 46.8% | 24.3% | ||
| Q3 25 | 51.4% | 25.9% | ||
| Q2 25 | 49.6% | 28.8% | ||
| Q1 25 | 50.0% | 24.1% | ||
| Q4 24 | 46.5% | 26.6% | ||
| Q3 24 | 53.3% | 27.4% | ||
| Q2 24 | 52.2% | 35.5% | ||
| Q1 24 | 52.4% | 28.7% |
| Q4 25 | 19.4% | 3.3% | ||
| Q3 25 | 13.2% | -3.5% | ||
| Q2 25 | 24.2% | 9.3% | ||
| Q1 25 | 21.9% | 4.1% | ||
| Q4 24 | 24.2% | 5.8% | ||
| Q3 24 | 29.8% | -1.7% | ||
| Q2 24 | 30.3% | 17.4% | ||
| Q1 24 | 27.9% | 8.2% |
| Q4 25 | 13.3% | 1.5% | ||
| Q3 25 | 9.0% | -4.0% | ||
| Q2 25 | 17.8% | 6.1% | ||
| Q1 25 | 14.8% | 1.8% | ||
| Q4 24 | 20.4% | 3.5% | ||
| Q3 24 | 21.1% | -2.1% | ||
| Q2 24 | 20.8% | 17.5% | ||
| Q1 24 | 25.1% | 5.7% |
| Q4 25 | $0.51 | $0.04 | ||
| Q3 25 | $0.37 | $-0.08 | ||
| Q2 25 | $0.64 | $0.19 | ||
| Q1 25 | $0.51 | $0.05 | ||
| Q4 24 | $0.74 | $0.10 | ||
| Q3 24 | $0.78 | $-0.04 | ||
| Q2 24 | $0.73 | $0.60 | ||
| Q1 24 | $0.81 | $0.17 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $22.4M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $363.2M |
| 総資産 | $1.6B | $548.6M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $22.4M | ||
| Q3 25 | $276.2M | $18.0M | ||
| Q2 25 | $231.8M | $25.2M | ||
| Q1 25 | $236.9M | $26.7M | ||
| Q4 24 | $221.6M | $39.1M | ||
| Q3 24 | $250.5M | $35.5M | ||
| Q2 24 | $217.8M | $60.8M | ||
| Q1 24 | $289.6M | $47.4M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $363.2M | ||
| Q3 25 | $776.7M | $364.4M | ||
| Q2 25 | $757.5M | $372.5M | ||
| Q1 25 | $751.3M | $366.9M | ||
| Q4 24 | $732.3M | $371.5M | ||
| Q3 24 | $727.7M | $380.0M | ||
| Q2 24 | $713.3M | $399.9M | ||
| Q1 24 | $672.4M | $376.4M |
| Q4 25 | $1.6B | $548.6M | ||
| Q3 25 | $1.7B | $554.6M | ||
| Q2 25 | $1.6B | $559.6M | ||
| Q1 25 | $1.6B | $578.9M | ||
| Q4 24 | $1.6B | $587.4M | ||
| Q3 24 | $1.5B | $571.3M | ||
| Q2 24 | $1.5B | $577.4M | ||
| Q1 24 | $1.6B | $570.6M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $27.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $16.3M |
| FCFマージンFCF / 売上 | 13.4% | 13.1% |
| 設備投資強度設備投資 / 売上 | 4.5% | 8.8% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 14.22× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $21.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $27.3M | ||
| Q3 25 | $52.6M | $-8.1M | ||
| Q2 25 | $35.6M | $40.8M | ||
| Q1 25 | $35.1M | $-9.8M | ||
| Q4 24 | $29.0M | $-7.4M | ||
| Q3 24 | $60.0M | $-30.8M | ||
| Q2 24 | $69.1M | $43.7M | ||
| Q1 24 | $55.3M | $25.2M |
| Q4 25 | $24.6M | $16.3M | ||
| Q3 25 | $47.2M | $-12.4M | ||
| Q2 25 | $25.0M | $33.5M | ||
| Q1 25 | $24.4M | $-16.1M | ||
| Q4 24 | $16.6M | $-10.7M | ||
| Q3 24 | $46.2M | $-35.5M | ||
| Q2 24 | $63.1M | $38.2M | ||
| Q1 24 | $46.5M | $7.0M |
| Q4 25 | 13.4% | 13.1% | ||
| Q3 25 | 24.6% | -14.6% | ||
| Q2 25 | 14.3% | 23.8% | ||
| Q1 25 | 14.3% | -13.9% | ||
| Q4 24 | 8.9% | -8.3% | ||
| Q3 24 | 24.1% | -40.2% | ||
| Q2 24 | 34.6% | 24.0% | ||
| Q1 24 | 27.1% | 5.1% |
| Q4 25 | 4.5% | 8.8% | ||
| Q3 25 | 2.8% | 5.0% | ||
| Q2 25 | 6.1% | 5.2% | ||
| Q1 25 | 6.3% | 5.4% | ||
| Q4 24 | 6.7% | 2.5% | ||
| Q3 24 | 7.2% | 5.3% | ||
| Q2 24 | 3.3% | 3.5% | ||
| Q1 24 | 5.1% | 13.2% |
| Q4 25 | 1.35× | 14.22× | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | 4.73× | ||
| Q1 25 | 1.39× | -4.68× | ||
| Q4 24 | 0.76× | -1.63× | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | 1.57× | ||
| Q1 24 | 1.28× | 3.20× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
SWBI
セグメントデータなし
